Scientists work to sharpen brain scans for future mental health breakthroughs
NCT ID NCT01266577
First seen Jun 27, 2026 · Last updated Jul 02, 2026 · Updated 3 times
Summary
This study aims to improve magnetic resonance imaging (MRI) and spectroscopy (MRS) techniques to better see and measure brain chemicals. Researchers will scan 300 healthy adults aged 18 to 65 to test and refine these imaging methods. The goal is to develop more accurate tools for studying brain activity and chemistry, which could help future research on psychiatric conditions.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- What this could lead to
- If successful, this could lead to better imaging tools for studying brain chemistry, which may help future research on psychiatric illnesses.
- What could go wrong
- This is an early-stage methods development study with no direct treatment or health benefit. It only involves healthy volunteers and focuses on improving technology, not curing any disease.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BRAIN MAPPING are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
National Institutes of Health Clinical Center
RECRUITINGBethesda, Maryland, 20892, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can eye movements reveal the Brain's visual priorities?
- A new eye on the brain: could this tracer unlock Addiction's secrets?
- First look: can a new drug candidate pass early safety tests in humans?
- A painless, contact-free vibration sensor may detect hidden heart and lung problems
- Can a Two-Pathway pill improve ED treatment? a new trial puts the combo to the test
- Could a common drug shield the brain from Alzheimer's?